/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ziv-aflibercept for DME provides BCVA gains, lower dosing burden


    Randomized control trial details

    The study recruited 135 eyes of 93 patients that were randomly assigned to intravitreal treatment with ziv-aflibercept 2.5 mg/0.1 mL, ziv-aflibercept 1.25 mg/0.05 mL, or bevacizumab 1.25 mg/0.05 mL. Ziv-aflibercept was administered as three loading doses at 4-week intervals and then every 8 weeks. Bevacizumab was administered on a monthly basis.

    A total of 123 eyes (83 patients) completed all visits. No eyes required retinal photocoagulation, vitrectomy, or cataract surgery. The mean number of injections administered was about 6.7 in each of the ziv-aflibercept groups and 11.6 for bevacizumab.

    BCVA analyses showed that compared with the bevacizumab-treated eyes, mean BCVA improvement in the 2.5 and 1.25 mg ziv-aflibercept groups was 0.20 and 0.16 logMAR greater, respectively. Percentages of eyes achieving >0.2 logMAR improvement of BCVA was also significantly greater in the ziv-aflibercept groups.

    Among eyes with initial BCVA ≤20/50, a 2-line improvement in BCVA was achieved in 95% of eyes treated with ziv-aflibercept 2.5 mg, 91% of those treated with ziv-aflibercept 1.25 mg, and 67% of bevacizumab-treated eyes.

    Overall, final CMT was <250 µm in 65% of eyes treated with ziv-aflibercept 2.5 mg, 53% of the eyes treated with ziv-aflibercept 1.25 mg, and 40% of bevacizumab-treated eyes.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results